Global systems biology, personalized medicine and molecular epidemiology

Molecular Systems Biology

Volumn 2, Issue , 2006, Pages

  Nicholson, Jeremy K ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DESIGN; DRUG METABOLISM; EDITORIAL; GENETIC VARIABILITY; HEALTH CARE; HUMAN; MEDICINE; METABOLISM; METABONOMICS; MOLECULAR EPIDEMIOLOGY; NONHUMAN; PATIENT ASSESSMENT; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHENOTYPE; POPULATION GENETICS; POPULATION RISK; PRESCRIPTION; PRIORITY JOURNAL; REGULATORY MECHANISM; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMS BIOLOGY; DEVELOPED COUNTRY; DEVELOPING COUNTRY; EPIDEMIOLOGY; ETHNIC AND RACIAL GROUPS; GENETICS; GENOTYPE; HEALTH SERVICE; INDIVIDUALITY;

DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; EPIDEMIOLOGY, MOLECULAR; GENOTYPE; HUMANS; INDIVIDUALITY; METABOLISM; PERSONAL HEALTH SERVICES; PHENOTYPE; POPULATION GROUPS; SYSTEMS BIOLOGY;

EID: 33750719994     PISSN: 17444292     EISSN: 17444292     Source Type: Journal    
DOI: 10.1038/msb4100095     Document Type: Editorial

References (28)

1. Brugman S, Klatter FA, Visser JTJ, Wildeboer-Veloo ACM, Harmsen HJM, Rozing J, Bos NA (2006) Antibiotic treatment partially protects against type 1 diabetes in the Bio-Breeding diabetes-prone rat. Is the gut microflora involved in the development of type 1 diabetes. Diabetologia 49: 2105-2108
2. Cavalli-Sforza LL, Feldman MW (2003) The application of molecular genetic approaches to the study of human evolution. Nat Genet 33: 266-275
3. Clayton TA, Lindon JC, Antti H, Charuel C, Hanton G, Provost JP, Le Net JL, Baker D, Walley RJ, Everett JE, Nicholson JK (2006) Pharmaco-metabonomic phenotyping and personalised drug treatment. Nature 440: 1073-1077
4. Dumas ME, Barton RH, Toye A, Cloarec O, Blancher C, Rothwell A, Fearnside J, Tatoud R, Blanc V, Lindon JC, Mitchell S, Holmes E, McCarthy MI, Scott J, Gauguier D, Nicholson JK (2006a) Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin resistant mice. Proc Natl Acad Sci USA 103: 12511-12516
5. Dumas ME, Maibaum EC, Teague C, Ueshima H, Zhou BF, Lindon JC, Nicholson JK, Stamler J, Elliott P, Chan Q, Holmes E (2006b) Assessment of analytical reproducibility of 1H NMR spectroscopy based metabonomics in large scale epidemiological studies. Anal Chem 78: 2199-2208
6. Eichelbaum M, Burk O (2001) CYP3A (2001) genetics in drug metabolism. Nat Med 7: 285-288
7. Gavaghan CL, Holmes E, Lenz E, Wilson ID, Nicholson JK (2000) An NMR-based metabonomic approach to investigate the biochemical consequences of genetic strain differences: application to the C57BL10J and Alpk:ApfCD mouse. FEBS Lett 484: 169-174
8. Gavaghan-McKee CL, Wilson ID, Nicholson JK (2006) Molecular phenotyping of nude and normal (Alpk:ApfCD, C57BL10J) mice via metabonomics. J Proteome Res 5: 378-384
9. Holmes E, Nicholson JK (2005) Gut microbiota strongly influences experimental rodent phenotypes. Toxicol Lett 87: 1-2
10. Lederberg J (2000) Infectious history. Science 288: 287-293
11. Martin FPJ, Verdu EF, Wang Y, Dumas ME, Yap IKS, Cloarec O, Bergonzelli GE, Corthesy-Theulaz I, Kochhar S, Holmes E, Lindon JC, Collins SM, Nicholson JK (2006) Transgenomic metabolic interactions in a mouse disease model: interactions of Trichinella spiralis infection with dietary Lactobacillus paracasei supplementation. J Proteome Res 5: 2185-2193
12. Meyer UA, Zanger UM (1997) Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 37: 269-296
13. Nebert DW, Menon AG (2001) Pharmacogenomics, ethnicity and susceptibility genes. Pharmacogenomics J 1: 541-549
14. Nebert DW, Nebert J, Vessell ES (2003) Pharmacogenomics and 'Individualized Drug Therapy'. High expectations and disappointing results. Am J Pharmacogenomics 3: 361-370
15. Nebert DW, Vessell ES (2004) Role of cytochrome P4501A in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics 5: 259-274
16. Nicholson JK, Connelly J, Lindon JC, Holmes E (2002) Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov 1: 153-161
17. Nicholson JK, Holmes E, Lindon JC, Wilson ID (2004) The challenges of modelling mammalian biocomplexity. Nat Biotechnol 22: 1268-1274
18. Nicholson JK, Holmes E, Wilson ID (2005) Gut microbes, mammalian metabolism and personalized healthcare. Nat Rev Microbiol 3: 2-8
19. Nicholson JK, Lindon JC, Holmes E (1999) 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR data. Xenobiotica 29: 1181-1189
20. Nicholson JK, Wilson ID (1989) High resolution proton NMR spectroscopy of biological fluids. Prog NMR Spectrosc 21: 449-501
21. Nicholson JK, Wilson ID (2003) Understanding 'global' systems biology: metabonomics and the continuum of metabolism. Nat Rev Drug Discov 2: 668-676
22. Plumb RS, Johnson KA, Rainville P, Smith BW, Wilson ID, Castro-Perez JM, Nicholson JK (2006) UPLC-MSE:a new approach for generating molecular fragment information for biomarker structure elucidation. Rapid Commun Mass Spectrom 20: 1989-1994
23. Raamsdonk LM, Teusink B, Broadhurst D, Zhang N, Hayes A, Walsh MC, Berden JA, Brindle KM, Kell DB, Rowland JJ, Westerhoff HV, van Dam K, Oliver SG (2001) A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations. Nat Biotechnol 19: 45-50
24. Rantalainen M, Cloarec O, Trygg J, Beckonert O, Wilson ID, Jackson D, Rowlinson R, Jones S, Rayner S, Nickson J, Tonge R, Wilkinson R, Mills JD, Nicholson JK, Holmes E (2006) Statistically integrated metabonomic-proteomic studies on a human prostate cancer xenograft model in mice. J Proteome Res (in press)
25. Srivastava P (2003) Drug metabolism and individualized medicine. Curr Drug Metab 4: 33-44
26. 1H NMR spectroscopy as a result of metabonomic screening of humans. Analyst 129: 259-264
27. Wang Y, Holmes E, Nicholson JK, Cloarec O, Chollet J, Tanner M, Singer B H, Utzinger J (2004) Metabonomic investigations in mice infected with Schistosoma mansoni: an approach for biomarker identification. Proc Natl Acad Sci USA 101: 12676-12681
28. Wilson ID, Nicholson JK, Castro-Perez J, Grainger JH, Johnson KA, Smith BW, Plumb RS (2005) High resolution 'ultra performance' liquid chromatography coupled to/oa-TOF mass spectrometry as a tool for differential metabolic pathway profiling in functional genomic studies. J Proteome Res 4: 591-598